10-Q: Clearside Biomedical Faces Going Concern Doubt Amid Strategic Review

Sentiment:

Quarterly Report 14 November 2025 4:10 PM

📋All filings for Clearside Biomedical, INC

Clearside Biomedical reports significant financial challenges, including a going concern warning and a strategic review, despite reduced net losses.

Delay expectedAll internal research and development programs have been paused as part of the strategic alternative process, which can only be resumed if the company is able to raise additional capital. This constitutes a delay in product candidate development.

Capital raiseThe company states it will need to obtain additional financing to fund future operations, including completing development, partnering, and potential commercialization of product candidates.Future cash needs may be financed through public or private equity offerings, license agreements, debt financings or restructurings, collaborations, strategic alliances, and marketing or distribution arrangements.The company may also be able to sell common stock under its existing Controlled Equity Offering SM Sales Agreement, subject to terms and market conditions.

Worse than expectedThe company explicitly states 'substantial doubt about the Company's ability to continue as a going concern within one year' and does not expect its cash to fund operations for the next 12 months.All internal research and development programs have been paused, indicating a severe curtailment of core business activities.A 'Reduction in Force' was implemented, terminating all employees and transitioning them to consulting roles, reflecting significant cost-cutting measures due to financial distress.The company is exploring a full range of strategic alternatives, including potential bankruptcy or winding down operations, which are indicators of a critical financial situation.The company received a Nasdaq notice for non-compliance with listing requirements, signaling potential delisting and further negative impact on stock value and liquidity.

Summary

Clearside Biomedical, Inc. (CLSD) reported a net loss of $6.0 million for the three months ended September 30, 2025, an improvement from $7.7 million in the same period of 2024.
For the nine months ended September 30, 2025, the net loss was $18.7 million, compared to $27.0 million for the nine months ended September 30, 2024.
Cash and cash equivalents significantly decreased to $6.8 million as of September 30, 2025, from $20.0 million at December 31, 2024.
The company has initiated a strategic review to explore options such as sale, license, merger, or divestiture of assets, and has paused all internal research and development programs.
A 'Reduction in Force' was implemented in July 2025, terminating all employees and transitioning them to consulting roles, incurring $2.3 million in severance costs in Q3 2025.
The company received an additional $2.9 million from HCR (Royalty Sub) in September 2025 in exchange for remaining SCS Microinjector technology assets, and the aggregate royalties required for the Purchase and Sale Agreement to expire were reduced from $110.5 million to $106.5 million.
A one-for-fifteen reverse stock split was effected on September 12, 2025.
The company received a Nasdaq notice on August 28, 2025, for non-compliance with the minimum Market Value of Listed Securities ($50 million) and has until February 24, 2026, to regain compliance.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, critically low cash balance, pausing of all R&D programs, significant reduction in force, and the exploration of strategic alternatives that include potential bankruptcy or winding down operations. While net losses decreased, this is largely attributed to severe cost-cutting rather than improved operational performance, and the Nasdaq delisting risk adds further negative pressure.

Positives

Net loss decreased to $6.0 million for Q3 2025 from $7.7 million for Q3 2024.
Net loss decreased to $18.7 million for 9M 2025 from $27.0 million for 9M 2024.
Net cash used in operating activities decreased to $16.0 million for 9M 2025 from $19.4 million for 9M 2024.
License and other revenue increased to $3.0 million for 9M 2025 from $1.4 million for 9M 2024, primarily due to $1.5 million in milestones from Arctic Vision.
Received an additional $2.9 million payment from HCR (Royalty Sub) in September 2025 for SCS Microinjector technology assets.
The aggregate royalties required for the Purchase and Sale Agreement to expire were reduced from $110.5 million to $106.5 million.

Negatives

Cash and cash equivalents declined significantly to $6.8 million as of September 30, 2025, from $20.0 million at December 31, 2024.
Total stockholders deficit worsened to $(53.9) million as of September 30, 2025, from $(38.9) million at December 31, 2024.
License and other revenue decreased to $0.2 million for Q3 2025 from $1.0 million for Q3 2024.
General and administrative expenses increased by $1.5 million for Q3 2025 and $0.9 million for 9M 2025, partly due to severance costs and professional fees.
Interest income decreased by $0.3 million for Q3 2025 and $0.8 million for 9M 2025 due to lower cash balances.
The company incurred $2.3 million in severance and other employee termination-related costs in Q3 2025 due to a 'Reduction in Force'.
All internal research and development programs have been paused.
The company received a Nasdaq notice for non-compliance with the minimum Market Value of Listed Securities ($50 million) and faces potential delisting.

Risks

Substantial doubt exists about the company's ability to continue as a going concern within one year, as current cash and cash equivalents are insufficient to fund operations for the next 12 months.
If a strategic alternative is not available, the company may be forced to file for bankruptcy or wind down operations, potentially resulting in a total loss of investment for stockholders.
The strategic review process may not result in any transaction or enhance stockholder value, and a failure to complete a strategic alternative could negatively impact investor perceptions and stock price.
Delisting from Nasdaq is a risk due to non-compliance with the minimum Market Value of Listed Securities, which could adversely affect stock liquidity and future financing capabilities.
The company has suffered recurring losses and negative cash flows from operations since inception and anticipates additional losses until significant revenue is generated.
Future cash needs will require additional financing through equity offerings, debt financings, license agreements, or other arrangements, which may not be available on commercially reasonable terms or at all.
Raising additional capital through equity or convertible debt securities will dilute existing ownership interests.
Macroeconomic conditions, including rising inflation and interest rates, and global conflicts, may negatively affect business growth and results of operations.

Future Outlook

The company does not expect its current cash and cash equivalents to fund planned operating expenses for the next 12 months from the filing date, raising substantial doubt about its ability to continue as a going concern. All internal research and development programs are paused, with resumption contingent on raising additional capital. The company is actively exploring a full range of strategic alternatives, including potential sale, license, merger, or divestiture of assets, and may be forced to file for bankruptcy or wind down operations if a suitable alternative is not found.

Management Comments

We announced plans to explore a full range of strategic alternatives to advance our SCS platform and drug development pipeline to maximize stockholder value.
If a strategic alternative is not available, we will be required to take additional actions to fund our operations, or we may be forced to file for bankruptcy or wind down our operations.
Based on our current plans and forecasted expenses, we do not expect our cash and cash equivalents will enable us to fund our planned operating expenses for the next 12 months from the date of this filing.
We paused all internal research and development programs which can be resumed if we are able to raise additional capital.

Industry Context

Clearside Biomedical operates in the highly competitive biopharmaceutical sector, specifically targeting ophthalmic indications with its suprachoroidal space (SCS) delivery platform. The company's financial distress and decision to pause R&D and explore strategic alternatives highlight the significant capital requirements and inherent risks in drug development, particularly for smaller biotech firms. The approval of XIPERE was a notable achievement for SCS delivery, but commercialization success and subsequent revenue generation have not been sufficient to sustain operations, reflecting broader challenges in bringing novel therapies to market and achieving profitability without substantial ongoing funding.

Comparison to Industry Standards

NA The filing does not provide specific comparisons to industry benchmarks or comparable companies/projects. The company's 'going concern' warning and strategic review indicate a significant deviation from typical industry growth and financial stability standards for a publicly traded biopharmaceutical company with an approved product.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and Chief Executive Officer	George Lasezkay (employee)	George Lasezkay (consultant)	July 17, 2025	Transitioned from employee to consulting role as part of a company-wide 'Reduction in Force'.
Chief Financial Officer	Charles A. Deignan (employee)	Charles A. Deignan (consultant)	July 17, 2025	Transitioned from employee to consulting role as part of a company-wide 'Reduction in Force'.
Key Personnel	Victor Chong (employee)	Victor Chong (consultant)	July 17, 2025	Transitioned from employee to consulting role as part of a company-wide 'Reduction in Force'.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Shares Increase	Stockholders approved an amendment to increase the authorized number of shares of common stock from 13,333,333 to 26,666,666.	May 30, 2025	Increases flexibility for future equity financing, but also potential for dilution.
Reverse Stock Split	A one-for-fifteen (1:15) reverse stock split of outstanding common stock was effected, with a corresponding reduction in authorized shares.	September 12, 2025	Aims to increase per-share price, potentially to meet Nasdaq listing requirements, but does not change overall market capitalization or fundamental value. Can be a negative signal to investors.

Legal Proceedings

The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

A member of the Company's Board of Directors was the chief executive officer of a vendor company until January 2025. As of December 31, 2024, the Company had $0.5 million in accounts payable and $0.3 million in accrued expense with this vendor. Expenses related to this vendor were $0.3 million for Q3 2024 and $0.5 million for 9M 2024.
The chair of the board of directors of BioCryst also serves on the Company's Board of Directors. License and other revenue related to the BioCryst License Agreement was $0.2 million for Q3 2025 ($81,000 for Q3 2024) and $0.5 million for 9M 2025 ($0.2 million for 9M 2024).
A former member of the Company's Board of Directors is the chief financial officer of Aura Biosciences. License and other revenue related to the Aura License Agreement was $945 for Q3 2025 and $4,185 for 9M 2025.

Stakeholder Impact

Shareholders face significant risk of dilution from potential future capital raises and a total loss of investment if the company is forced into bankruptcy or liquidation.
Employees (now consultants) have experienced a 'Reduction in Force', indicating job insecurity and a shift in employment terms.
Customers and partners (licensees like Bausch + Lomb, Arctic Vision, BioCryst) may face uncertainty regarding the company's long-term ability to support its SCS platform and supply Microinjectors.
Creditors (e.g., HCR for royalty payments) face increased risk due to the company's 'going concern' warning and financial instability.

Next Steps

Continue to explore a full range of strategic alternatives to advance the SCS platform and drug development pipeline, including sale, license, merger, or divestiture of assets.
Seek additional financing through public or private equity offerings, license agreements, debt financings, or other arrangements to fund future operations.
Regain compliance with Nasdaq's minimum Market Value of Listed Securities requirement by February 24, 2026, to avoid delisting.
Potentially resume internal research and development programs if additional capital is successfully raised.

Key Dates

Date	Description
May 26, 2011	Company incorporated in the State of Delaware.
September 2016	Issued warrants to purchase up to 1,986 shares of common stock at $161.10 per share in connection with a loan agreement.
July 3, 2019	Effective date of License Agreement with Aura Biosciences, Inc.
August 29, 2019	Option and License Agreement with REGENXBIO Inc. entered into.
October 18, 2019	FDA issued a complete response letter related to the XIPERE NDA.
October 22, 2019	Entered into License Agreement with Bausch + Lomb.
March 10, 2020	Entered into License Agreement with Arctic Vision (Hong Kong) Limited.
August 2021	Entered into an amendment to the Arctic License Agreement to expand territories.
September 2021	Entered into a second amendment to the Arctic Vision License Agreement to expand territories to include Australia and New Zealand.
October 2021	FDA approval of XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.
First quarter of 2022	Bausch + Lomb launched XIPERE in the United States.
August 8, 2022	Company, through Royalty Sub, entered into the Purchase and Sale Agreement with HCR, selling rights to certain royalties and milestone payments for up to $65 million. Also entered into Contribution and Servicing Agreement and Pledge and Security Agreement.
November 2022	Signed an amended office lease agreement for corporate headquarters.
May 2023	Entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. to sell up to $50.0 million in common stock.
November 1, 2023	Entered into the BioCryst License Agreement, granting an exclusive, worldwide license for SCS Microinjector for avoralstat delivery.
December 22, 2023	Entered into a Letter Agreement with Agent amending the Purchase and Sale Agreement, waiving rights to the First Milestone Payment.
January 31, 2024	Entered into a fourth amendment to the license agreement with Emory University and Georgia Tech Research Corporation, reducing sublicense percentage and revising annual maintenance fees.
February 6, 2024	Entered into a securities purchase agreement for a registered direct offering, issuing common stock and warrants for net proceeds of $13.9 million.
March 31, 2025	Deadline for payment to Licensor of Sublicensee Percentage for qualifying payments received by the Company from a Sublicensee after July 1, 2023, but prior to January 1, 2025.
May 30, 2025	Stockholders approved an amendment to increase authorized common stock from 13,333,333 to 26,666,666 shares.
July 2025	Announced plans to explore a full range of strategic alternatives and implemented a 'Reduction in Force' terminating all employees and transitioning them to consulting roles.
July 17, 2025	Separation and Consulting Agreements for George Lasezkay, Charles Deignan, and Victor Chong were dated.
August 28, 2025	Received notice from Nasdaq regarding non-compliance with the minimum Market Value of Listed Securities requirement.
August 29, 2025	Stockholders approved a proposal to effect a reverse stock split and corresponding reduction in authorized shares.
September 4, 2025	Board of directors approved the filing of a certificate of amendment to affect the reverse stock split. Entered into an Omnibus Amendment Agreement with Royalty Sub and HCR entities, receiving an additional $2.9 million and adjusting royalty terms.
September 12, 2025	Effected a one-for-fifteen (1:15) reverse stock split.
September 30, 2025	End of the quarterly period covered by this report.
October 1st of each year (2025-2028)	Annual Maintenance Fee payments due to Emory University and Georgia Tech Research Corporation.
November 12, 2025	Date of common stock outstanding count (5,233,981 shares).
November 14, 2025	Date of filing of this 10-Q report.
February 24, 2026	Deadline to regain compliance with Nasdaq's minimum Market Value of Listed Securities requirement.
September 2026	Expiration of warrants issued in September 2016.
August 9, 2029	Expiration of warrants issued in February 2024.

Recommendation

strong sell

The company explicitly states 'substantial doubt about its ability to continue as a going concern' and does not have sufficient cash to fund operations for the next 12 months. All internal R&D programs are paused, and a significant 'Reduction in Force' has occurred. The company is exploring strategic alternatives, including potential bankruptcy or winding down operations, which could lead to a total loss for stockholders. Furthermore, the Nasdaq delisting notice adds to the severe negative outlook. While net losses have decreased, this is primarily due to drastic cost-cutting measures rather than sustainable operational improvements. These factors indicate extreme financial distress and a high probability of significant further share price decline or complete loss of investment.

Keywords

Clearside Biomedical, CLSD, 10-Q, Biopharmaceutical, Suprachoroidal Space, SCS Microinjector, XIPERE, Financial Results, Going Concern, Strategic Alternatives, Reverse Stock Split, Nasdaq Delisting Risk, Research and Development Pause, Reduction in Force, Royalty Agreement, Ophthalmology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.